| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
Papers In Press, published online ahead of print October 1, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Endocrinology, Diabetes and Clinical Nutrition, University Hospital Basel, Basel 4031
Corresponding Author: ukeller{at}uhbs.ch
Kinetics of apolipoprotein B (apo B) and apolipoprotein AI (apo AI) in plasma lipoproteins was assessed in 8 male patients with mixed hyperlipidemia at baseline and after 8 weeks of therapy with either atorvastatin 80 mg q.d. or micronised fenofibrate 200 mg q.d. in an open cross-over study. Both increased hepatic production and decreased catabolism of very low density lipoproteins accounted for the elevation of plasma cholesterol and triglycerides at baseline. Atorvastatin significantly decreased plasma triglycerides, total, VLDL and LDL cholesterol and apo B concentrations (-65%, -36%, -57%, -40% and –33%, respectively, p<0.05). Kinetic analysis revealed that atorvastatin stimulated the catabolism of apo B containing lipoproteins, enhanced the delipidation of VLDL1 and decreased their production in some patients. Fenofibrate lowered plasma triglycerides and VLDL cholesterol (-57% and –64%, resp., p<0.05) due to both enhanced delipidation of VLDL1 and VLDL2 and an increase in VLDL1 catabolism. LDL cholesterol and apo B concentrations remained unchanged secondary to a decrease in LDL catabolism. Changes of HDL particle composition accounted for the increase of HDL cholesterol during atorvastatin and fenofibrate (18% and 23%, p< 0.01). Only fenofibrate increased apo AI concentrations through enhanced apo AI synthesis (45%, p<0.05). We conclude that in subjects with mixed hyperlipidemia atorvastatin exerts additional beneficial effects on the metabolism of apo B containing lipoproteins unrelated to an increase in LDL receptor activity and that fenofibrate but not atorvastatin increases apo AI production and plasma turnover.
Revised on September 17, 2003
Accepted on September 23, 2003
Effects of atorvastatin versus fenofibrate on apolipoprotein B-100 and apolipoprotein A-I kinetics in mixed hyperlipidemia
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  E. M. M. Ooi, G. F. Watts, P. J. Nestel, D. Sviridov, A. Hoang, and P. H. R. Barrett Dose-Dependent Regulation of High-Density Lipoprotein Metabolism with Rosuvastatin in the Metabolic Syndrome J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 430 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lamon-Fava, M. R. Diffenderfer, P. H. R. Barrett, A. Buchsbaum, N. R. Matthan, A. H. Lichtenstein, G. G. Dolnikowski, K. Horvath, B. F. Asztalos, V. Zago, et al. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism J. Lipid Res., August 1, 2007; 48(8): 1746 - 1753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Christidis, E. N. Liberopoulos, A. I. Kakafika, G. A. Miltiadous, M. Cariolou, E. S. Ganotakis, D. P. Mikhailidis, and M. S. Elisaf The effect of apolipoprotein e polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2006; 11(3): 211 - 221. [Abstract] [PDF]
|
|
|
|
|
|
S. Rashid, B. W. Patterson, and G. F. Lewis Thematic review series: Patient-Oriented Research. What have we learned about HDL metabolism from kinetics studies in humans? J. Lipid Res., August 1, 2006; 47(8): 1631 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. G. Parhofer and P. H. R. Barrett Thematic review series: Patient-Oriented Research. What we have learned about VLDL and LDL metabolism from human kinetics studies J. Lipid Res., August 1, 2006; 47(8): 1620 - 1630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C Chan, G. F Watts, M. N Nguyen, and P H. R Barrett Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity Am. J. Clinical Nutrition, July 1, 2006; 84(1): 37 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. N. Ginsberg REVIEW: Efficacy and Mechanisms of Action of Statins in the Treatment of Diabetic Dyslipidemia J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 383 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. L. Isley, J. M. Miles, B. W. Patterson, and W. S. Harris The effect of high-dose simvastatin on triglyceride-rich lipoprotein metabolism in patients with type 2 diabetes mellitus J. Lipid Res., January 1, 2006; 47(1): 193 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Duez, B. Lefebvre, P. Poulain, I. P. Torra, F. Percevault, G. Luc, J. M. Peters, F. J. Gonzalez, R. Gineste, S. Helleboid, et al. Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator-Activated Receptor {alpha} Modulation Arterioscler. Thromb. Vasc. Biol., March 1, 2005; 25(3): 585 - 591. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |
